Gadopentetate dimeglumine excretion into human breast milk during lactation

被引:65
|
作者
Kubik-Huch, RA
Gottstein-Aalame, NM
Frenzel, T
Seifert, B
Puchert, E
Wittek, S
Debatin, JF
机构
[1] Univ Zurich Hosp, Dept Radiol, CH-8091 Zurich, Switzerland
[2] Univ Zurich Hosp, Clin Obstet, CH-8091 Zurich, Switzerland
[3] Schering, Berlin, Germany
[4] Univ Zurich, Dept Biostat, Zurich, Switzerland
关键词
breast; contrast media; complications; effects; toxicity; gadolinium; infants; newborn; magnetic resonance (MR);
D O I
10.1148/radiology.216.2.r00au09555
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To analyze the amount of gadopentetate dimeglumine excreted into human breast milk following intravenous injection of a clinical dose. MATERIALS AND METHODS: Gadopentelate dimeglumine was injected intravenously in 20 lactating women (23-38 years of age). Breast-feeding was interrupted for at least 24 hours. Serial samples of expressed milk were collected and analyzed for gadolinium concentration by means of inductively coupled plasma atomic emission spectrometry at a wavelength of 342.247 nm. RESULTS: The cumulative amount of gadolinium excreted in human breast milk during 24 hours was 0.57 mu mol +/- 0.71 (SD range, 0.05-3.0 mu mol). the excreted dose was thus less than 0.04% of the administered intravenous dose (range, 0.001%-0.04%; mean, 0.009% +/- 0.010) for all cases. CONCLUSION: Less than 0.04% of administered gadopentetate dimeglumine is excreted into human breast milk. The amount transferred to a nursing infant orally would be far more than 100 times less than the permitted intravenous dose (200 mu mol per kilogram of body weight) for neonates. The recommendation of a 24-hour, suspension of breast-feeding for lactating women should thus be reconsidered.
引用
收藏
页码:555 / 558
页数:4
相关论文
共 50 条
  • [41] EXCRETION OF LORATADINE IN HUMAN-BREAST MILK
    HILBERT, J
    RADWANSKI, E
    AFFRIME, MB
    PERENTESIS, G
    SYMCHOWICZ, S
    ZAMPAGLIONE, N
    JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 28 (03): : 234 - 239
  • [42] EXCRETION OF ACYCLOVIR IN HUMAN BREAST-MILK
    DON, PC
    KIZNER, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1991, 25 (02) : 342 - 342
  • [43] ACYCLOVIR EXCRETION IN HUMAN BREAST-MILK
    TADDIO, A
    KLEIN, J
    KOREN, G
    ANNALS OF PHARMACOTHERAPY, 1994, 28 (05) : 585 - 587
  • [44] EXCRETION OF QUAZEPAM INTO HUMAN-BREAST MILK
    HILBERT, JM
    GURAL, RP
    SYMCHOWICZ, S
    ZAMPAGLIONE, N
    JOURNAL OF CLINICAL PHARMACOLOGY, 1984, 24 (10): : 457 - 462
  • [45] EXCRETION OF MORPHINE IN HUMAN-BREAST MILK
    FEILBERG, VL
    ROSENBORG, D
    CHRISTENSEN, CB
    MOGENSEN, JV
    ACTA ANAESTHESIOLOGICA SCANDINAVICA, 1989, 33 (05) : 426 - 428
  • [46] EXCRETION OF CEFPROZIL INTO HUMAN BREAST-MILK
    SHYU, WC
    SHAH, VR
    CAMPBELL, DA
    VENITZ, J
    JAGANATHAN, V
    PITTMAN, KA
    WILBER, RB
    BARBHAIYA, RH
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1992, 36 (05) : 938 - 941
  • [47] EXCRETION OF NOSCAPINE IN HUMAN-BREAST MILK
    OLSSON, B
    BOLME, P
    DAHLSTROM, B
    MARCUS, C
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 30 (02) : 213 - 215
  • [48] Contrast-Enhanced MR Mammography: Improvement in Breast Lesion Detection and Characterization with Gadobenate Dimeglumine Compared to Gadopentetate Dimeglumine
    Dominelli, V
    Pediconi, F.
    Catalano, C.
    Padula, S.
    Roselli, A.
    Cagioli, S.
    Passariello, R.
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2009, 192 (05)
  • [49] INADVERTENT-IV ADMINISTRATION OF GADOPENTETATE DIMEGLUMINE DURING EARLY-PREGNANCY
    BARKHOF, F
    HEIJBOER, RJJ
    ALGRA, PR
    AMERICAN JOURNAL OF ROENTGENOLOGY, 1992, 158 (05) : 1171 - 1171
  • [50] Transfer of Montelukast into Human Milk During Lactation
    Datta, Palika
    Rewers-Felkins, Kathleen
    Baker, Teresa
    Hale, Thomas W.
    BREASTFEEDING MEDICINE, 2017, 12 (01) : 54 - 57